Stock listing
NASDAQ:AMIX Autonomix Medical, Inc. Stock
Home listing (NASDAQ) of Autonomix Medical, Inc.
Follow Autonomix Medical, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AMIX
$0.891 USD -0.199 (-18.2%)
Close on Nov 20, 2026
- Day range
- $0.880 – $1.040 USDNov 20, 2026
- Volume
- 219,017 sharesNov 20, 2026
- Market cap
- $1.82M USDAt the close on Nov 20, 2026 · price × 2.05M shares outstanding
- 52-week range
- $0.880 – $24.680 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.19M USDMedian day 85,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AMIX · Home | $0.891 USD | -0.199 (-18.2%) | 219,017 | $1.040 | $1.040 | $0.880 | $1.090 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AMIX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.891 | -0.199 | -18.2% | $1.040 | $1.040 | $0.880 | 219,017 | |
| $1.090 | +0.010 | +0.9% | $1.080 | $1.150 | $1.080 | 105,810 | |
| $1.080 | -0.020 | -1.8% | $1.070 | $1.220 | $1.060 | 114,129 | |
| $1.100 | -0.270 | -19.7% | $1.330 | $1.410 | $0.932 | 546,287 | |
| $1.370 | +0.015 | +1.1% | $1.340 | $1.489 | $1.330 | 200,562 | |
| $1.355 | -0.125 | -8.4% | $1.440 | $1.440 | $1.305 | 489,042 | |
| $1.480 | -0.370 | -20.0% | $1.650 | $1.670 | $1.420 | 1,317,813 | |
| $1.850 | +0.150 | +8.8% | $1.810 | $3.300 | $1.620 | 72,180,709 | |
| $1.700 | +0.180 | +11.8% | $1.565 | $1.770 | $1.530 | 342,888 | |
| $1.520 | 0.000 | 0.0% | $1.510 | $1.680 | $1.460 | 85,900 | |
| $1.520 | -0.090 | -5.6% | $1.660 | $1.670 | $1.520 | 65,200 | |
| $1.610 | -0.050 | -3.0% | $1.730 | $1.780 | $1.610 | 81,200 | |
| $1.660 | -0.020 | -1.2% | $1.710 | $1.730 | $1.634 | 43,000 | |
| $1.680 | -0.130 | -7.2% | $1.850 | $1.880 | $1.680 | 51,400 | |
| $1.810 | -0.230 | -11.3% | $2.080 | $2.150 | $1.810 | 134,500 | |
| $2.040 | -0.110 | -5.1% | $2.110 | $2.219 | $2.040 | 53,800 | |
| $2.150 | +0.080 | +3.9% | $2.160 | $2.165 | $2.110 | 29,700 | |
| $2.070 | -0.030 | -1.4% | $2.080 | $2.139 | $2.060 | 36,900 | |
| $2.100 | -0.320 | -13.2% | $2.340 | $2.436 | $2.050 | 158,300 | |
| $2.420 | -0.080 | -3.2% | $2.500 | $2.500 | $2.415 | 60,200 | |
| $2.500 | -0.070 | -2.7% | $2.640 | $2.640 | $2.500 | 28,000 | |
| $2.570 | -0.040 | -1.5% | $2.610 | $2.700 | $2.560 | 15,000 | |
| $2.610 | -0.040 | -1.5% | $2.690 | $2.690 | $2.600 | 27,000 | |
| $2.650 | -0.195 | -6.9% | $2.900 | $2.900 | $2.630 | 37,900 | |
| $2.845 | -0.085 | -2.9% | $2.930 | $3.000 | $2.800 | 31,200 | |
| $2.930 | +0.030 | +1.0% | $2.890 | $2.960 | $2.810 | 31,800 | |
| $2.900 | -0.110 | -3.7% | $3.030 | $3.070 | $2.900 | 56,400 | |
| $3.010 | -0.090 | -2.9% | $3.090 | $3.165 | $3.000 | 30,800 | |
| $3.100 | -0.010 | -0.3% | $3.130 | $3.190 | $3.100 | 41,900 | |
| $3.110 | -0.020 | -0.6% | $3.100 | $3.170 | $3.080 | 33,100 | |
| $3.130 | -0.280 | -8.2% | $3.400 | $3.400 | $3.100 | 87,100 | |
| $3.410 | -0.060 | -1.7% | $3.490 | $3.590 | $3.390 | 56,200 | |
| $3.470 | -0.070 | -2.0% | $3.540 | $3.600 | $3.450 | 63,300 | |
| $3.540 | -0.240 | -6.3% | $3.680 | $3.730 | $3.540 | 133,300 | |
| $3.780 | -0.140 | -3.6% | $3.990 | $4.040 | $3.620 | 2,574,700 | |
| $3.920 | +0.090 | +2.3% | $3.840 | $4.200 | $3.795 | 133,300 | |
| $3.830 | +0.080 | +2.1% | $3.830 | $3.910 | $3.600 | 401,800 | |
| $3.750 | -0.080 | -2.1% | $3.865 | $3.885 | $3.730 | 47,500 | |
| $3.830 | -0.190 | -4.7% | $3.800 | $3.942 | $3.773 | 74,200 | |
| $4.020 | -0.050 | -1.2% | $4.095 | $4.300 | $3.910 | 262,800 | |
| $4.070 | +0.090 | +2.3% | $4.050 | $4.180 | $3.940 | 47,900 | |
| $3.980 | -0.150 | -3.6% | $4.110 | $4.110 | $3.900 | 55,200 | |
| $4.130 | +0.080 | +2.0% | $4.000 | $4.220 | $4.000 | 60,900 | |
| $4.050 | -0.160 | -3.8% | $4.130 | $4.290 | $3.910 | 83,800 | |
| $4.210 | -0.070 | -1.6% | $4.390 | $4.390 | $4.180 | 32,200 | |
| $4.280 | +0.160 | +3.9% | $4.050 | $4.380 | $4.050 | 67,200 | |
| $4.120 | -0.090 | -2.1% | $4.000 | $4.220 | $3.910 | 151,200 | |
| $4.210 | -0.120 | -2.8% | $4.260 | $4.450 | $4.130 | 127,500 | |
| $4.330 | -0.040 | -0.9% | $4.300 | $4.420 | $4.230 | 52,300 | |
| $4.370 | -0.015 | -0.3% | $4.390 | $4.520 | $4.302 | 54,000 | |
| $4.385 | -0.185 | -4.0% | $4.480 | $4.510 | $4.320 | 85,400 | |
| $4.570 | -0.010 | -0.2% | $4.600 | $4.666 | $4.400 | 87,100 | |
| $4.580 | -0.010 | -0.2% | $4.470 | $4.750 | $4.470 | 78,500 | |
| $4.590 | -0.090 | -1.9% | $4.590 | $4.680 | $4.444 | 66,000 | |
| $4.680 | +0.180 | +4.0% | $4.475 | $4.810 | $4.310 | 193,300 | |
| $4.500 | -0.240 | -5.1% | $4.650 | $4.681 | $4.390 | 100,800 | |
| $4.740 | -0.090 | -1.9% | $4.670 | $4.800 | $4.530 | 125,900 | |
| $4.830 | -0.490 | -9.2% | $5.200 | $5.200 | $4.660 | 360,400 | |
| $5.320 | -0.310 | -5.5% | $5.370 | $5.610 | $5.080 | 312,200 | |
| $5.630 | -0.750 | -11.8% | $6.210 | $6.290 | $5.620 | 362,900 | |
| $6.380 | -0.810 | -11.3% | $6.830 | $7.300 | $6.311 | 1,438,900 | |
| $7.190 | +1.820 | +33.9% | $7.610 | $9.990 | $7.145 | 28,618,100 | |
| $5.370 | +0.100 | +1.9% | $5.240 | $5.590 | $4.970 | 15,602,000 | |
| $5.270 | 0.000 | 0.0% | $5.190 | $5.870 | $5.190 | 109,100 | |
| $5.270 | -0.640 | -10.8% | $5.790 | $5.970 | $5.140 | 177,000 |
Splits
2 splits since 2024 · NASDAQ:AMIX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-21 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:AMIX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Autonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026
Latest deck · Nov 20, 2026
Investor Presentation (November 2026)
Investor deck · 17 slides
Latest news
Autonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026
Nov 12, 2026
Closed $1.36 (-8.4%) on Nov 12, 2026
Autonomix Medical Granted New U.S. Patent Strengthening Proprietary Catheter-Based Sensing Technology
Nov 10, 2026
Closed $1.85 (+8.8%) on Nov 10, 2026
Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation
Oct 2, 2026
Closed $3.78 (-3.6%) on Oct 2, 2026
Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance
Sep 30, 2026
Closed $3.83 (+2.1%) on Sep 30, 2026
Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform
Sep 24, 2026
Closed $4.07 (+2.3%) on Sep 24, 2026
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors
Sep 16, 2026
Closed $4.12 (-2.1%) on Sep 16, 2026
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
Sep 1, 2026
Closed $4.74 (-1.9%) on Sep 1, 2026
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery
Aug 26, 2026
Closed $6.38 (-11.3%) on Aug 26, 2026
Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
Aug 24, 2026
Closed $7.19 (+33.9%) on Aug 25, 2026
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
Aug 12, 2026
Closed $7.54 (-17.4%) on Aug 12, 2026
Autonomix Medical, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 35 in the last 12 months · 109 in all · newest Nov 12, 2026 · oldest 2024
- Decks
- 7 decks · latest Nov 20, 2026
Where Autonomix Medical, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AMIX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:AMIX | BOATS | United States | USD |
Valuation
Price/book 0.3× against a median of 0.3×: 4th lowest of 9 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$5.87M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.79
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Autonomix Medical, Inc. · NASDAQ:AMIX | US$1.82M | −US$5.87M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.79 |
| LKL International Bhd. · MYX:LKL | US$2.36M | US$4.15M | n/a | 0.3× | n/a | 0.1× | −46.9% | 0.2× | n/a |
| RemSleep Holdings, Inc. · OTC:RMSL | US$2.09M | US$2.06M | n/a | 123× | n/a | n/a | n/a | n/a | -0.01 |
| Fuse Medical, Inc. · OTC:FZMD | US$2.03M | US$4.31M | 14.8× | 0.5× | 7.8× | 0.3× | 1.5% | 0.4× | 0.54 |
| Nuwellis, Inc. · NASDAQ:NUWE | US$1.84M | −US$6.31M | n/a | −0.7× | n/a | 0.2× | −152.8% | 0.0× | 2.26 |
| Vivos Therapeutics, Inc. · NASDAQ:VVOS | US$1.83M | US$2.11M | n/a | 0.1× | n/a | 0.8× | −107.1% | 0.2× | 1.41 |
| Adagio Medical Holdings, Inc · NASDAQ:ADGM | US$1.72M | US$636,010 | 2.1× | n/a | n/a | 0.1× | n/a | 0.1× | 0.69 |
| Escalon Medical Corp. · OTC:ESMC | US$1.71M | −US$1.96M | 0.4× | −0.1× | n/a | 0.3× | 32.8% | 0.0× | -0.06 |
| Therma Bright Inc. · TSXV:THRM | US$1.66M | US$1.64M | n/a | 17.3× | n/a | n/a | n/a | n/a | -0.15 |
| Nexalin Technology, Inc. · NASDAQ:NXL | US$1.45M | US$1.88M | n/a | 6.8× | n/a | 5.5× | n/a | 4.7× | 0.52 |
| Zero Candida Technologies Inc. · TSXV:ZCT | US$1.43M | −US$59,292 | n/a | n/a | n/a | 2.2× | n/a | 0.0× | -0.17 |
| Median of the others | US$1.77M | US$1.76M | 2.1× | 0.4× | 7.8× | 0.3× | −46.9% | 0.1× | 0.52 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 40.80 USD · Analysts' mean
- EPS, year to Mar 2027
- -8.60 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Brad Hauser | President and Chief Executive Officer |
| Trent Smith | Chief Financial Officer |
| Jennifer Cook | Chief Business Officer |
| Robert Schwartz | Chief Medical Officer |
| Walter V. Klemp | Executive Chairman |
Board
| Director | Role |
|---|---|
| Walter V. Klemp | Executive Chairman |
| Christopher Capelli | Director |
| David Robins | Director |
| Jonathan P. Foster | Director |
| Lori Bisson | Executive Vice Chairman |
| Sandra Cohen Kalter | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Nov 10, 2026 · Before open | +8.8% |
| Q1 2027 | Aug 12, 2026 | −24.8% |
| Q4 2026 | Jun 3, 2026 | −1.2% |
| Q3 2026 | Feb 11, 2026 · After close | −1.8% |
| Q2 2026 | Nov 12, 2025 · After close | −13.8% |
| Q1 2026 | Aug 13, 2025 · After close | +1.8% |
| Q4 2025 | May 29, 2025 · After close | −2.7% |
| Q3 2025 | Feb 13, 2025 · Before open | +4.8% |
| Q2 2025 | Nov 8, 2024 · After close | −4.7% |
| Q1 2025 | Aug 28, 2024 | −2.5% |
All 11 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | May 29, 2024 | +2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 17 slides | Nov 20, 2026 |
| Investor Presentation (January 2026) | Investor deck | 17 slides | Jan 9, 2026 |
| Investor Presentation (April 2025) | Investor deck | 18 slides | Apr 30, 2025 |
| Investor Presentation (January 2025) | Investor deck | 18 slides | Jan 22, 2025 |
| Corporate Update (June 2024) | Corporate update | 13 slides | Jun 18, 2024 |
| Investor Presentation (March 2024) | Investor deck | 23 slides | Mar 4, 2024 |
| Reset Pharma — Investor Presentation (August 2023) | Investor deck | 36 slides | August 2023 |
Financings
| Raise | Date |
|---|---|
| Common stock issued on exercise of July 2026 warrants, with new unregistered Series E-1 and E-2 warrants Announced: about US$4.9M · US$5.75 a share · Warrants at US$6.25 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) | Aug 25, 2026 |
| Common stock issued on exercise of November 2025 warrants Announced: about US$2.6M · US$6 a share · ½ warrant at US$5.75 for 66 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) | Jul 14, 2026 |
| Private placement of shares of common stock (or pre-funded warrants) and Series C warrants Announced: about US$5M · US$1.1107 a share · ½ warrant at US$0.8607 for 66 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) | Nov 18, 2025 |
| Warrant exercise of shares of common stock upon exercise of existing warrants Announced: about US$2.5M · US$1.723 a share · ½ warrant at US$1.723 for 66 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Working capital and general corporate purposes | Jul 22, 2025 |
| Public offering of common stock units and pre-funded warrant units Closed: US$10M raised · US$6.54 a unit · 1 warrant at US$6.54 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Fund its clinical trial, other research and development, development of intellectual property, and working capital | Nov 25, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | |
| Cost of revenue | 12.0K | 183.0K | 81.0K | ||
| Gross profit | -12.0K | -183.0K | -81.0K | ||
| Research and development | 7.14M | 4.72M | 2.23M | 745.0K | 4.07K |
| Selling, general and administrative | 9.89M | 6.86M | 5.25M | 1.25M | 13.6M |
| Operating income | -17.0M | -11.6M | -12.0M | -1.99M | -13.6M |
| Depreciation and amortization | 12.0K | 183.0K | 81.0K | 0 | 13.6M |
| EBITDA | -17.0M | -11.4M | -11.9M | -1.99M | 0 |
| Interest expense | 0 | 176.0K | 79.0K | 0 | 218.1K |
| Income before tax | -16.7M | -11.4M | -15.4M | -1.99M | -13.3M |
| Income tax | 0 | 0 | 0 | 0 | -13.6M |
| Net income | -16.7M | -11.4M | -15.4M | -1.99M | -13.3M |
| Earnings per share, basic | -2.32 | -6.46 | -14.82 | -0.17 | -297.87 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cash and equivalents | 7.00M | 9.14M | 8.61M | 865.0K | 2.04M |
| Current assets | 7.58M | 9.61M | 9.39M | 865.0K | 2.05M |
| Property, plant and equipment | 19.0K | 21.0K | 16.0K | 0 | |
| Total assets | 7.60M | 9.81M | 9.41M | 865.0K | 2.05M |
| Accounts payable | 700.0K | 676.0K | 492.0K | 173.0K | 91.6K |
| Current liabilities | 1.71M | 1.71M | 777.0K | 221.0K | 93.2K |
| Long-term debt | 1.00M | ||||
| Total debt | 1.00M | 0 | |||
| Total liabilities | 1.71M | 1.71M | 1.78M | 221.0K | 93.2K |
| Shareholders' equity | 5.89M | 8.10M | 7.63M | 644.0K | 1.96M |
| Shares outstanding | 542.3K | 2.50M | 942.6K | 12.3M | 44.7K |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cash from operations | -12.3M | -8.26M | -6.60M | -1.85M | -387.3K |
| Capital spending | -10.0K | -14.0K | -19.0K | 0 | -3 |
| Free cash flow | -12.3M | -8.27M | -6.62M | -1.85M | -387.3K |
| Cash from investing | -10.0K | -14.0K | -19.0K | 0 | |
| Cash from financing | 10.2M | 8.80M | 14.4M | 675.0K | 2.43M |
| Change in cash | -2.13M | 528.0K | 7.74M | -1.18M | 2.04M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Sep 16, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 16, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Sep 16, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Sep 14, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 14, 2026 | Meeting notice | SEC |
All 151 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B5 · Prospectus | Sep 11, 2026 | Offer document | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Sep 4, 2026 | Meeting notice | SEC |
| S-3 · Registration statement | Sep 4, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 26, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 5, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Jul 31, 2026 | Offer document | SEC |
| S-3 · Registration statement | Jul 28, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 28, 2026 | Current report | SEC |
| 8-K · Current report | Jul 15, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 10, 2026 | Current report | SEC |
| 8-K · Current report | Jun 24, 2026 | Current report | SEC |
| 10-K/A · Annual report, amended | Jun 15, 2026 | Annual report | SEC |
| 10-K · Annual report | May 27, 2026 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Apr 2, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Feb 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jan 16, 2026 | Current report | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 12, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 26, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 19, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Meeting outcome | SEC |
| 424B3 · Prospectus | Oct 6, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 29, 2025 | Other filings | SEC |
| S-1 · Registration statement | Sep 23, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Sep 12, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 12, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Sep 11, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 4, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 3, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Aug 29, 2025 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Aug 28, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| 8-K · Current report | Aug 26, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 25, 2025 | Offer document | SEC |
| S-1 · Registration statement | Aug 20, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jul 28, 2025 | Annual report | SEC |
| 424B3 · Prospectus | Jul 22, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 22, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jul 14, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jul 3, 2025 | Offer document | SEC |
| 10-K · Annual report | May 29, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 30, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 12, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 10, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Mar 7, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 7, 2025 | Other filings | SEC |
| S-3 · Registration statement | Feb 28, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 28, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Feb 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 22, 2025 | Current report | SEC |
| SC 13G · Big-stake notice | Dec 3, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 27, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 25, 2024 | Material contract | SEC |
| 424B4 · Prospectus | Nov 25, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 19, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 19, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Nov 12, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2024 | Current report | SEC |
| S-1 · Registration statement | Nov 1, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 28, 2024 | Current report | SEC |
| 8-K · Current report | Oct 17, 2024 | Meeting outcome | SEC |
| SC 13G · Big-stake notice | Oct 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 20, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Sep 4, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 4, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Aug 23, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| UPLOAD · Letter from the SEC | Aug 2, 2024 | Other filings | SEC |
| 10-K/A · Annual report, amended | Jul 26, 2024 | Annual report | SEC |
| 4 · Change in ownership | Jul 26, 2024 | Insider trade | SEC |
| DRS · Draft registration statement | Jul 25, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 15, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2024 | Current report | SEC |
| 8-K · Current report | Jun 17, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | May 31, 2024 | Offer document | SEC |
| 10-K · Annual report | May 31, 2024 | Annual report | SEC |
| 8-K · Current report | May 31, 2024 | Results | SEC |
| 8-K · Current report | Mar 4, 2024 | Current report | SEC |
| SC 13D · Big-stake notice | Feb 26, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Feb 15, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 13, 2024 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Feb 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 31, 2024 | Financing | SEC |
| 3 · Initial statement of ownership | Jan 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 26, 2024 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Jan 26, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jan 26, 2024 | Other filings | SEC |
| 253G2 | Jan 26, 2024 | Other filings | SEC |
| QUALIF | Jan 26, 2024 | Other filings | SEC |
| 1-A POS | Jan 19, 2024 | Other filings | SEC |
| 253G2 | Jan 11, 2024 | Other filings | SEC |
| 1-SA | Jan 9, 2024 | Other filings | SEC |
| 253G2 | Oct 16, 2023 | Other filings | SEC |
| QUALIF | Oct 2, 2023 | Other filings | SEC |
| 1-A/A | Sep 29, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 15, 2023 | Other filings | SEC |
| 1-A/A | Sep 15, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 6, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 21, 2023 | Other filings | SEC |
| 1-A/A | Aug 21, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 3, 2023 | Other filings | SEC |
| 1-A | Jul 6, 2023 | Other filings | SEC |
| D | Jun 1, 2023 | Other filings | SEC |
| D | Mar 20, 2023 | Other filings | SEC |
| D | Apr 6, 2022 | Other filings | SEC |
| D | Sep 3, 2014 | Other filings | SEC |
Cap table
Built by 6ix from Autonomix Medical, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 2,045,193
- Fully diluted
- 3,578,289
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 2,045,193 | Nov 6, 2026 |
| Warrants | 1,533,096 | Nov 25, 2024 |
Warrants and options
| Lot |
|---|
| Warrants · US$6.54 · expire about Nov 2029 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 2,045,193 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bradley Hauser Other companies: SkinHealth Systems Inc. (Chief Operating Officer · Apr 19, 2023 – Nov 29, 2023 · Past); Soliton Inc (CEO and President, Director · Feb 19, 2019 – Dec 16, 2021 · Past); Zeltiq Aesthetics Inc (SVP, Research and Development · Jan 8, 2016 – Apr 28, 2017 · Past) | CEO and President · Since at least Jun 17, 2024 |
| Jonathan P. Foster Other companies: Empery Digital Inc. (Director · Since at least Jul 17, 2025); Moleculin Biotech, Inc. (Chief Financial Officer · Since at least Dec 26, 2023) | Director · Since at least Jan 26, 2024 |
| Walter V. Klemp Other companies: Moleculin Biotech, Inc. (Chairman, President and Chief Executive Officer · Since at least Jun 2, 2016); Soliton Inc (Executive Chairman, Director · Feb 19, 2019 – Dec 16, 2021 · Past) | Executive Chairman · Since at least Jan 26, 2024 |
| Christopher Capelli Other companies: Soliton Inc (CSO and Vice Chairman, Director · Feb 19, 2019 – Dec 16, 2021 · Past) | Director · Since at least Jan 26, 2024 |
| Lori Bisson Other companies: Soliton Inc (Chief Financial Officer · Feb 19, 2019 – Dec 16, 2021 · Past) | Executive Vice Chairman · Since at least Jan 26, 2024 |
| Trent Smith Other companies: InfuSystems Holdings, Inc. (Exec VP,CAO & Corp Controller · Aug 11, 2016 – Sep 7, 2017 · Past) | Chief Financial Officer · Since at least Jan 26, 2024 |
| Brad Hauser | President and Chief Executive Officer · Since at least Sep 8, 2026 |
| David Robins | Director · Since at least Jan 26, 2024 |
| Jennifer Cook | Chief Business Officer · Since at least Nov 5, 2026 |
| Robert Schwartz | Chief Medical Officer · Since at least Sep 1, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Sandra Cohen Kalter | Director · Since at least Sep 16, 2026 |
Log in to ask 6ix AI your own questions about Autonomix Medical, Inc.